XML 48 R39.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue Recognition (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2018
USD ($)
Sep. 30, 2019
USD ($)
Feb. 28, 2019
USD ($)
Apr. 30, 2016
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Sep. 30, 2019
USD ($)
item
Sep. 30, 2018
USD ($)
Revenue recognized                 $ 1,000  
Agreement term       4 years            
Deferred revenue, noncurrent $ 40,058 $ 56,174     $ 56,174       56,174  
Other assets 3,317 12,679     12,679       12,679  
Deferred revenue 44,189 81,841     81,841       81,841  
Deferred revenue, current portion 4,131 25,667     25,667       25,667  
Total revenues         77,909   $ 65,280   219,088 $ 190,689
Deferred revenue, long-term portion 40,058 56,174     56,174       56,174  
Research and development                    
Costs         200       300  
Product                    
Revenue recognized         600   700   1,900 2,500
Total revenues         66,936   62,662   $ 195,399 177,284
Product | Minimum                    
Billing collection period (in months)                 9 months  
Product | Maximum                    
Billing collection period (in months)                 12 months  
Licensing and other                    
Total revenues         10,973   2,618   $ 23,689 13,405
IVD kits and genetic testing services                    
Revenue recognized                 500  
Storage services                    
Revenue recognized                 $ 300  
Evercord | Processing and storage services                    
Number of performance obligations | item                 2  
Evercord | Processing and storage services | Minimum                    
Billing collection period (in months)                 6 months  
Evercord | Processing and storage services | Maximum                    
Billing collection period (in months)                 18 months  
Evercord | Processing and storage services | Alternate                    
Billing collection period (in months)                 12 months  
Qiagen                    
Revenue recognized         0   $ 100 $ 5,500 $ 600 $ 5,700
Revenue, remaining performance obligation   40,000     40,000       40,000  
Deferred revenue, noncurrent   36,265     36,265       36,265  
Deferred revenue   38,570     38,570       38,570  
Deferred revenue, current portion   2,305     2,305       2,305  
Deferred revenue, long-term portion   36,265     36,265       36,265  
Qiagen | The Qiagen Agreement                    
Revenue recognized                 $ 100  
Agreement term                 10 years  
Qiagen | Volume, regulatory and commercial milestones                    
Revenue recognized $ 5,000                  
Revenue, remaining performance obligation   10,000     10,000       $ 10,000  
Laboratory distribution partners | Product | Minimum                    
Billing collection period (in months)                 2 months  
Laboratory distribution partners | Product | Maximum                    
Billing collection period (in months)                 3 months  
BGI                    
Revenue recognized         6,900       $ 11,900  
Proceeds from license agreement     $ 50,000     $ 35,600        
Receivable   2,500     2,500       2,500  
Agreement term     10 years              
Deferred revenue, noncurrent   16,050     16,050       16,050  
Deferred revenue   28,099     28,099       28,099  
Deferred revenue, current portion   12,049     12,049       12,049  
Deferred revenue, long-term portion   16,050     16,050       16,050  
BGI | Research and development                    
Costs         800       1,200  
BGI | Sequencing services                    
Other assets   6,000     6,000       6,000  
BGI | Sequencing products                    
Other assets   4,000     4,000       4,000  
BGI | Sequencing products and services                    
Other assets   10,000     10,000       10,000  
Foundation                    
Revenue recognized         0          
Proceeds from license agreement         13,300          
Receivable   1,000     1,000       1,000  
Deferred revenue, noncurrent   3,859     3,859       3,859  
Deferred revenue   14,250     14,250       14,250  
Deferred revenue, current portion   10,391     10,391       10,391  
Deferred revenue, long-term portion   3,859     $ 3,859       $ 3,859  
Foundation | Upfront licensing fees and prepaid revenues                    
Proceeds from license agreement   13,300                
Foundation | Developmental, regulatory, and commercial milestones                    
Proceeds from license agreement   $ 32,000